ScreenerHero

AVLNAvalyn Pharma Inc. Common Stock

NAS · US · Healthcare · Biotechnology · avalynpharma.com
38.37USD-1.54%Mkt Cap: 1.70B $P/E: —

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company pr…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.70B $
Enterprise Value1.31B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-85.20M $
Revenue/Share—
Last Price38.37 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees55
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-19.54
PEG—
EV/EBITDA-11.94
EV/Revenue—
P/S—
P/B4.13
EPS (TTM)-2.22
EPS (Forward)-1.90
52W Range
24.1590% of range40.03
52W High40.03 USD
52W Low24.15 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE35.70%
ROA-57.23%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-81.48M $
CapEx (TTM)344.00K $
FCF Margin—
FCF Yield—
Net Debt-335.32M $
Net Debt/EBITDA3.05
Balance Sheet
Debt/Equity-0.01
Current Ratio33.12
Quick Ratio32.76
Book Value/Sh8.985 USD
Cash/Share7.949 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)62.25 USD
Upside (mean)+62.2%
Target Range52.00 USD – 80.00 USD
$52.00+62.2% to mean$80.00
# Analysts4
Ownership
Shares Out.44.33M
Float27.41M
Insiders0.00%
Institutions102.28%
Short Interest
Short Ratio6.5d
Short % Float4.55%
Short % Out.4.55%
Shares Short2.02M
Short (prev mo.)2.17M
Technical
SMA 5030.85 (+24.4%)
SMA 20029.89 (+28.4%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)203.32K
Avg Vol (10d)198.84K
Technical Indicators
RSI (14)66.2
MACD2.5278
MACD Signal2.1242
MACD Hist.+0.4036
BB Upper42.32 USD
BB Middle33.71 USD
BB Lower25.11 USD
BB Width51.04%
ATR (14)2.422 USD
Vol Ratio (20d)0.92x